This can occur on the condition that CD8+ T cells recognize shared tumor antigens between chemotherapy-sensitive tumor cells and BCSCs, and also that BCSCs present these antigens in the context of MHC class I. This concept of endogenous or in situ vaccination should be explored in greater depth as a strategy to decrease metastasis and improve patient survival. This evidence concerns the gene CD8A and neoplasm.